CTLA4 and non-small cell lung carcinoma: The data we present here suggest that a combination of BEMPEG and anti-CTLA-4 with local control could be an effective alternative treatment option for patients with NSCLC that is not responsive to anti-PD1/PDL1 therapies, and clinical investigation is warranted to test this.